Transcript
Fidelity Representative (0:00)
Fidelity Active ETFs have the flexibility to shift and transform as markets do the same. So instead of just riding an index, they can seek to outperform it by adapting to market conditions and pursuing new opportunities as they emerge. And while you get the potential outperformance of an actively managed fund, you can still buy and sell it on your terms. Just like any other etf. Markets can change in real time. Make sure your ETF can too. Learn more@fidelity.com ActiveETFs before investing in any exchange traded fund, you should consider its investment objectives, risks, charges and expenses. Contact Fidelity for a prospectus, an offering circular, or if available, a summary prospectus containing this information. Read it carefully. While active ETFs offer the potential to outperform an index, these products may more significantly trail an index as compared with passive ETFs. ETFs are subject to market fluctuation and the risks of their underlying investments. ETFs are subject to management fees and other expenses Fidelity Brokerage Services LLC Member NYSE SIPC.
Podcast Host (Only Murders in the Building) (1:01)
Welcome to Only Murders in.
Jim Cramer (1:03)
The Building the Official Podcast.
Michael Ciro Creighton (1:04)
Join me Michael Ciro Creighton as we go behind the scenes with some of the amazing actors, writers and crew from Season five.
Podcast Guest or Actor (1:11)
The audience should never stop suspecting anything.
Podcast Host (Only Murders in the Building) (1:14)
How can you not be funny crawling.
Podcast Guest or Actor (1:16)
Around on a coffin?
Podcast Host (Only Murders in the Building) (1:18)
Yeah, that's true.
Michael Ciro Creighton (1:19)
Catch Only Murders in the Building Official Podcast now streaming wherever you get your podcasts and watch Only Murders in the Building streaming on Hulu and Hulu on Disney for bundle subscribers. Terms apply.
Mad Money Disclaimer Narrator (1:29)
Sam.
Jim Cramer (1:53)
Hey, I'm Kramer. Welcome to Mad Money. Welcome to Crame America. Other people may Friends I'm just trying to make you a little money. My job is not just to entertain, but to teach. Put it in context. So call me at 1-800-743- CNBC. Tweet me imkramer not that long ago, pretty much everybody assumed that the next non tech stock to cross the trillion dollar threshold would be the stock of Eli Lilly. Why not? They've developed a weight loss and diabetes wonder drug with incredible prospect. This market plays many tricks on us every day, including today where The Dow dipped 126 points as we declined 0.13% and the Nasdaq edge down 0.07%. The anomaly this time it looks like the next trillion dollar stock won't be Eli Lilly. If anything, it's more likely to be the stock of J.P. morgan, a bank. Right now, Lilly's market capitalization is roughly $724 billion, but JP Morgan's at just over 850. 50 billion. Up 29% for the year. Meanwhile, Lilly's down oh so slightly. To me, this is a monumental move, people. A bank stock putting on that kind of market cap right on the eve of an incredibly important Fed meeting where everyone seems to be expecting a quarter point rate cut despite a recent uptick in inflation. What's going on here? First, understand the trillion dollar barrier is really hard to cross. Right now there are only nine members of the club in video at an astonishing 4.2%, 4.2 trillion. Then Microsoft close behind a 3.8 trillion Apple 3.5 trillion Alphabet which just crossed the $3 trillion threshold. Amazon at $2.5 trillion. Matt at $2 trillion. Broadcom at $1.7 trillion. And there comes Tesla yen, $1.4 trillion. And at last, hanging on by a thread is Berkshire Hathaway at $1.06 trillion. They're all more or less tech companies except for Berkshire. Oh, I thought Lilly would be next. The GOP Dash ones are just that huge. Today, Lilly announced plans to build a $5 billion manufacturing plant in Richmond, Virginia. As we told members of the investing club this morning, this facility marks the first of four, four American plans for targeting cancer and autoimmune drugs. They also need another plan for the pill version of the GLP1 drug, which hasn't been approved yet, but could turn out to be much bigger than the current injectable version of the drug. When you consider all the indications for this thing, including the already approved chronic weight management, diabetes and obstructive sleep apnea indications, and the fact that it might be approved for heart failure, hypertension and even chronic kidney disease, well, you can see why the betting line favored Lulu across the trillion dollar finish line first. But Lilly stock has been stalled in part because it has a vicious, some would say desperate, rival in the form of Novo Nordisk, which is doing quite poorly but has a very good compound. Plus, you aren't supposed to buy drug stocks if the Fed's going to cut interest rates. They are toxic at this point in the business cycle because it should accelerate the economy. So you should avoid so called safety drug stocks. And of course, the President seems to be hostile to the industry. They're building plants in America that could help Lily. Meanwhile, like a horse that's bided its time but is now at the far turn, J.P. morgan stock is putting on a run for the roses move that's as breathtaking as it is obscure what's propelling it first. It's not the only bank that's making a ferocious move. Citigroup for example, which had been in the doldrums for so so long, just crossed the $100 mark. What a 43% rally for the Citigroup star. That's a remarkable move in itself. Wells Fargo and Bank of America have been climbing to up more than 15% each. The so called investment banks Goldman Sachs and Morgan Stanley have been running like crazy with Goldman up 37%, Morgan Stanley of 24%. But if you ask me, the real rocket fuel, it's the expansion of what we call the price to earnings multiple or what we will pay for the company's earnings. Right now people are simply willing to pay more for the banks. We don't talk enough about the P E price to earnings multiple around here. A topic to which I spend a lot of time. Time in my next book, believe me, how to Make Money in Any Market comes out in two weeks because it's just so darn important. See, I don't think people realize that the price earnings multiple is at the heart. It's the fundament about how stocks trade. The multiple can rise even when the earnings estimates stay the same. That's called multiple expansion. It can move up a stock. Or the multiple can stay the same when the earnings estimates rise, which gives you a higher stock price too. In the case of the banks, it's both. That's right, both the earnings are going up and the price earnings multiples increase. See, at the same time it's remarkable because we're less than 24 hours away from a Fed meeting that would normally upset the financials if it backfires. And if you want to know what it means for a rate cut to backfire, stay tuned for the rest of the show. Right now though, the market's saying that the Fed doesn't matter to the bank stocks, which is nuts because the Fed matters immensely to the actual banks. Now some of that is because of this multiple expansion I just referred to. JP Morgan stock has been consistently selling for about 414 times its earnings for many, many years. Dramatically lower than the 22 times earnings bogey of the S&P 500. But it's been levitating alongside the earnings estimates all year. Now JP Morgan sells for 15.7 times this year's numbers, up from 14. Goldman Sachs and Morgan Stanley have also making gigantic moves. They now sell at 16.9 and 17.5 times earnings respectively. It is what we call a wholesale revision and it's only gaining steam now. Kudos to Mike Mayo, the uber bullish bank analyst at Wells Fargo who has a terrific piece out just today entitled Goliath is Winning. He upped his price targets for all these banks, making it very clear that the capital markets are really getting hot with some terrific tailwinds like Trump, deregulation, even credit quality, which has been remarkably good during this period. His favorite has been Citigroup, which CEO Jane Fraser has rescued from Murray obscurity. Recall, I happen like Wells Fargo where Mayo toils because CEO Charlie Sharp has resurrected this bank, this time from regulatory hardship. That said, JP Morgan's got something special. It excels at so many things. Lending, capital markets, trading and perhaps most important, statesmanship. With CEO Jamie Dimon performing at a level that's rare for any industry. JP Morgan has always been a top quality bank, but it's now become a fantastic place to work and its global reach is unmatched. There's a reason its market cap is so much bigger than the other major banks. Can this continue? I have to tell you, if you look at the forward multiple, meaning how much JP Morgan's trading on versus next year's earnings estimates, the answer is a resounding yes. Because this one sells for just 15 times the 2026 estimates. That's puny. Goldman Sachs and Morgan Stanley trade at roughly the same levels. But Wells Fargo, bank of America and Citigroup sell it ridiculously low, around 10 to 12 times next year's numbers. That's not sustainable. It's going to go higher. At the end of the day the price journeys multiple is the arbiter of what's cheap and what's expensive on next year's earnings estimates. And you're talking cheap, cheap, cheap. So yeah, my original prediction will likely be wrong. Eli well is probably not the next non tech stock to cross the trillion dollar barrier. But man, what a way to be wrong. I'd much rather have a market led by the banks and a market led by big pharma. The bottom line, I've been waiting for years for the banks to get higher priced earnings multiples. They're incredibly important to the broader market. When the banks are winning, it's a terrific sign for the overall trading. Remember this tomorrow if the averages take a hit from the Fed because once multiple expansion starts, it's not easy reverse we might be okay. These are hard fought moves and I bet that they're just at the beginning. Julio in Pennsylvania. Julio.
